The KEEPER™ trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

This publication has 14 references indexed in Scilit:

• Levetiracetam, a New Antiepileptic Agent: Lack of In Vitro and In Vivo Pharmacokinetic Interaction with Valproic Acid
  Epilepsia, 2003
• Dose–response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy
  Epilepsy Research, 2001
• Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers
  Epilepsy Research, 2001
• Long-term continuation of levetiracetam in patients with refractory epilepsy
  Neurology, 2001
• Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating Monotherapy
  Epilepsia, 2000
• Levetiracetam for partial seizures
  Neurology, 2000
• Effect of Levetiracetam on Epilepsy‐Related Quality of Life
  Epilepsia, 2000
• Absence of Pharmacokinetic Drug Interaction of Levetiracetam with Phenytoin in Patients with Epilepsy Determined by New Technique
  The Journal of Clinical Pharmacology, 2000
• A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy
  Seizure, 2000
• Proposal for Revised Classification of Epilepsies and Epileptic Syndromes
  Epilepsia, 1989